![](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/21369035-735674514-aileron_logo_Logo-100x79.jpeg)
Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
Announced positive data from Cohort 1 of the ongoing Phase 1b clinical trial of LTI-03 evaluating low dose LTI-03 (2.5 mg BID) in idiopathic pulmonary fibrosis (“IPF”) patients, with positive trends observed in seven of the eight biomarkers evaluated …